TRENTON — British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer. The drug is already sold under the ...
Consumer ads in support of GlaxoSmithKline’s prostate drug Avodart overstate its efficacy and present misleading claims, the FDA said in a letter to the company. The ad in question—a 60-second TV spot ...
Full results of a big study testing a drug for preventing prostate cancer show a higher risk of heart failure, a surprise finding that could dampen enthusiasm for expanding its use. On Monday, ...
PHILADELPHIA A new study that will be published in the Journal of Urology shows that men with enlarged prostates who took a combination of two medications, Avodart and tamsulosin hydrochloride, the ...
LONDON — GlaxoSmithKline withdrew all regulatory approval applications for a drug designed to cut men's risk of developing prostate cancer. The drug maker announced it no longer would pursue global ...
PHILADELPHIA, Jan. 18 /PRNewswire/ -- A study to be published in the February issue of the Journal of Urology shows that men with enlarged prostates who took a combination of two medications, AVODART ...
Men at an above-normal risk of prostate cancer may be able to reduce their risk of developing the disease by taking a drug already on the market. In research reported Wednesday, the drug dutasteride, ...
GlaxoSmithKline cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any ...
The FDA gave GlaxoSmithKline a lesson in geometry last week when it sent the company a warning letter over its "misleading" claims for Avodart, a prostate reduction drug. FDA's main objection was the ...
(Boston) -- Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic ...
LONDON, March 29 (Reuters) - GlaxoSmithKline has re-submitted its application to U.S. regulators for a new use of its Avodart drug in preventing prostate cancer. Sign up here. The British-based ...
CHICAGO -- GlaxoSmithKline PLC's Avodart drug lowered the risk of prostate cancer by 23% in men with elevated risk of the disease, a new study found. The findings suggest that the drug, known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback